Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Italy
  4. Borsa Italiana
  5. Recordati
  6. Summary
    REC   IT0003828271

RECORDATI

(REC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Borsa Italiana
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
52.56(c) 52.48(c) 51.1(c) 51.86(c) 50.6(c) Last
118 596 288 176 331 661 294 592 679 073 Volume
-0.64% -0.15% -2.63% +1.49% -2.43% Change
More quotes
Estimated financial data (e)
Sales 2021 1 591 M 1 866 M 1 866 M
Net income 2021 401 M 470 M 470 M
Net Debt 2021 787 M 923 M 923 M
P/E ratio 2021 26,0x
Yield 2021 2,21%
Sales 2022 1 713 M 2 009 M 2 009 M
Net income 2022 432 M 507 M 507 M
Net Debt 2022 725 M 850 M 850 M
P/E ratio 2022 25,0x
Yield 2022 2,36%
Capitalization 10 391 M 12 197 M 12 183 M
EV / Sales 2021 7,03x
EV / Sales 2022 6,49x
Nbr of Employees 4 446
Free-Float 46,6%
More Financials
Company
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system,... 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
More about the company
Ratings of Recordati
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about RECORDATI
07/30RECORDATI : Public disclosure
PU
07/29Recordati Industria Chimica E Farmaceutica S.P.A. Reports Earnings Results fo..
CI
07/29Recordati Revises Revenue Guidance for the Full Year of 2021
CI
07/29RECORDATI : Confirms 2021 Guidance
MT
07/29RECORDATI : First half of 2021 results approved, revenue +1.4%, ebitda -3.4%, ne..
PU
07/16RECORDATI : CEO to Transition to Chairman Role, Successor CEO Named
MT
07/16RECORDATI : Rob Koremans new Chief Executive Officer effective 1 December 2021, ..
PU
07/14RECORDATI : Supports the forestami project
PU
07/09RECORDATI : Italy's Recordati Commences Process to Reinforce Governance
MT
07/09RECORDATI : Strengthening of the corporate governance
PU
06/25ANALYST RECOMMENDATIONS : Accenture, Comcast, DoorDash, Intel, Roku...
05/25RECORDATI : The tenth edition of the arrigo recordati international prize for sc..
PU
05/24RECORDATI : Ex-dividend day for final dividend
FA
05/06Recordati Industria Chimica E Farmaceutica S.P.A. Provides Earnings Guidance ..
CI
05/06Recordati Industria Chimica E Farmaceutica S.P.A. Provides Earnings Guidance ..
CI
More news
News in other languages on RECORDATI
09/17L'agenda della prossima settimana
09/17BORSA I. EQUITY MTF : in luce B.Unicem
09/17BORSA : commento di chiusura
09/17RECORDATI : Barclays avvia copertura con equal weight
09/17OPINIONES DE LOS ANALISTAS DEL DÍA : Repsol, Ferrari, ENI, Rothschild, Lonza, Ga..
More news
Analyst Recommendations on RECORDATI
More recommendations
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | REC | IT0003828271 | MarketScreener
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 50,60 €
Average target price 49,03 €
Spread / Average Target -3,11%
EPS Revisions
Managers and Directors
Andrea Recordati Chief Executive Officer
Luigi Felice La Corte Group Chief Financial Officer
Alfredo Altavilla Chairman
Raffaele Sabia Senior VP-Pharmaceutical Research & Development
Michaela Castelli Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RECORDATI11.63%12 197
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604